|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
NOTE: If you attended the live CE activity titled "Strategies To Decrease Vancomycin-associated Nephrotoxicity - What Is Their Worth?" that was held on October 2, 2018 at the SIDP Annual Meeting in San Francisco, California, AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-18-380-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.
This activity will be divided into two different strategies to decrease Vancomycin-associated nephrotoxicity. The first will examine the risk of concurrent piperacillin/tazobactam and vancomycin in terms of nephrotoxicity. Faculty will discuss alternatives to reduce nephrotoxicity, empiricism in gram negative coverage and strategies to mitigate nephrotoxicity risk. The second strategy will focus on dosing Vancomycin using troughs versus AUC(area under the curve) and will examine benefits and downsides of each as well as the available Bayesian software.
This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.
The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:
- Examine strategies to decrease vancomycin-associated nephrotoxicity.
- Evaluate the potential risks of implementing a strategy.
- Evaluate the potential benefits of implementing a strategy.
Kari A. Mergenhagen PharmD, BCPS AQ-ID
Infectious Diseases Pharmacist
VA Western New York Healthcare System
Emi Minejima, PharmD
Assistant Professor of Clinical Pharmacy
USC School of Pharmacy
Release Date: 10-2-2018
Expiration Date: 10-2-2021
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-380-H01-P has been assigned to this home-study knowledge-based activity (initial release date 10-2-2018). This activity is approved for 0.75 contact hours (0.075 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Mergenhagen and Dr. Minejima have no relevant commercial or financial relationships to disclose.
Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is partially supported by an educational grant from Accelerate Diagnostics, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
|Activity Number||Credit Amount||Accreditation Period|
|0221-9999-18-380-H01-P||0.75 Contact Hours||October 02, 2018 - October 02, 2021|